Bank of New York Mellon’s Xenetic Biosciences XBIO Stock Holding History

Bank of New York Mellon’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-108	Closed	-$21K	–	4261
2018 Q4	$21K	Buy	+108	New	+$32.7K	﹤0.01%	4154

Other funds holding XBIO

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

Bank of New York Mellon's XBIO Position: Q1 2019 in Review

Bank of New York Mellon sold out of Xenetic Biosciences (XBIO) in Q1 2019, closing a stake of 108 shares — an estimated $21K sold.

Bank of New York Mellon first reported a position in XBIO in Q4 2018 and held it in 1 quarter. The position peaked at $21K in Q4 2018. 9 funds tracked by Wall St. Rank hold XBIO as of Q1 2019.

Bank of New York Mellon reported no remaining Xenetic Biosciences position as of Q1 2019 after selling out during the quarter.
Bank of New York Mellon sold 108 Xenetic Biosciences shares in Q1 2019, an estimated $21K.
Bank of New York Mellon first reported a position in Xenetic Biosciences in Q4 2018 and held it in 1 quarter.
Bank of New York Mellon's Xenetic Biosciences position peaked at $21K in Q4 2018.
9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2019.

Based on Bank of New York Mellon's 13F filing for Q1 2019, filed 14 May 2019.